A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Thomas CashElizabeth FoxXiaowei LiuCharles G MinardJoel M ReidAdrienne C ScheckBrenda J WeigelCynthia WetmorePublished in: Pediatric blood & cancer (2021)
Although the MTD of prexasertib was not defined by this study, 150 mg/m2 administered i.v. on days 1 and 15 of a 28-day cycle was determined to be the RP2D.